ProQR Therapeutics N.V.
Close on Oct 19, 2026
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | $2.03M | $-0.13 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 13, 2024 | Before market open | – | – | – |
Press releases
Announcements ProQR Therapeutics filed with the SEC
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer
EX-99.1 to Form 6-K
Index to Unaudited Interim Condensed Consolidated Financial Statements
EX-99.1 to Form 6-K
ProQR Announces Second Quarter 2026 Operating and Financial Results
EX-99.2 to Form 6-K
ProQR Announces Second Quarter 2026
EX-99.1 to Form 6-K
ProQR Prices $50.0 Million Underwritten Registered
EX-99.1 to Form 6-K
ProQR Announces Positive Phase 1 Target Engagement
EX-99.1 to Form 6-K
Index to Unaudited Condensed Consolidated Financial Statements
EX-99.1 to Form 6-K
ProQR Announces First Quarter 2026 Operating and Financial Results
EX-99.2 to Form 6-K
Announces First Quarter 2026 Operating and Financial Results
EX-99.1 to Form 6-K
General Meeting of Shareholders to be Held June 2, 2026
EX-99.1 to Form 6-K
ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V.
EX-99.2 to Form 6-K
2026 ANNUAL GENERAL MEETING OF
EX-99.3 to Form 6-K
Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
EX-99.1 to Form 6-K
ProQR Therapeutics – Investor & Analyst Event - April 8, 2026
EX-99.1 to Form 6-K
ProQR Highlights Pipeline Expansion and Multiple Upcoming
EX-99.2 to Form 6-K
ProQR Announces Partnership with Ginkgo
EX-99.1 to Form 6-K
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline
EX-99.1 to Form 6-K
Announces Year End 2025 Operating and Financial Results
EX-99.1 to Form 6-K
ProQR Announces Planned Changes to Board Composition
EX-99.1 to Form 6-K
ProQR Announces Encouraging AX-0810 Phase 1 Safety
EX-99.1 to Form 6-K
Index to Unaudited Condensed Consolidated Financial Statements
EX-99.1 to Form 6-K
ProQR Announces Third Quarter 2025 Operating and Financial Results
EX-99.2 to Form 6-K
ProQR Therapeutics – Investor & Analyst Event 2
EX-99.1 to Form 6-K
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual
EX-99.1 to Form 6-K
Index to Unaudited Condensed Consolidated Financial Statements
EX-99.1 to Form 6-K
ProQR Announces Second Quarter 2025 Operating and Financial Results
EX-99.2 to Form 6-K
ProQR Announces CTA Submission for Phase 1 Study of
EX-99.1 to Form 6-K
Index to Unaudited Condensed Consolidated Financial Statements
EX-99.1 to Form 6-K
ProQR Announces First Quarter 2025 Operating and Financial Results
EX-99.2 to Form 6-K
ProQR Announces Annual General Meeting
EX-99.1 to Form 6-K
ProQR Therapeutics N.V. | Zernikedreef 9 | 2333 CK
EX-99.2 to Form 6-K
Explanatory Notes to the Agenda
EX-99.3 to Form 6-K
ProQR Strengthens Leadership with Appointments of CFO
EX-99.1 to Form 6-K
Year End 2024 Operating and Financial Results
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
EX-99.1 to Form 6-K
ProQR Therapeutics to Host Virtual Analyst
EX-99.1 to Form 6-K
Index to Unaudited Condensed Consolidated Financial Statements
EX-99.1 to Form 6-K